CA2673667A1 - Crystalline forms glyt1 - Google Patents

Crystalline forms glyt1 Download PDF

Info

Publication number
CA2673667A1
CA2673667A1 CA002673667A CA2673667A CA2673667A1 CA 2673667 A1 CA2673667 A1 CA 2673667A1 CA 002673667 A CA002673667 A CA 002673667A CA 2673667 A CA2673667 A CA 2673667A CA 2673667 A1 CA2673667 A1 CA 2673667A1
Authority
CA
Canada
Prior art keywords
methyl
piperazin
methanesulfonyl
trifluoro
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002673667A
Other languages
English (en)
French (fr)
Inventor
Andre Bubendorf
Annette Deynet-Vucenovic
Ralph Diodone
Olaf Grassmann
Kai Lindenstruth
Emmanuel Pinard
Franziska E. Rohrer
Urs Schwitter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38988312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2673667(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2673667A1 publication Critical patent/CA2673667A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CA002673667A 2006-12-28 2007-12-18 Crystalline forms glyt1 Abandoned CA2673667A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06127269 2006-12-28
EP06127269.6 2006-12-28
PCT/EP2007/064104 WO2008080821A1 (en) 2006-12-28 2007-12-18 Crystalline forms glyt1

Publications (1)

Publication Number Publication Date
CA2673667A1 true CA2673667A1 (en) 2008-07-10

Family

ID=38988312

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002673667A Abandoned CA2673667A1 (en) 2006-12-28 2007-12-18 Crystalline forms glyt1

Country Status (33)

Country Link
US (5) US20080214561A1 (enExample)
EP (1) EP2114405B1 (enExample)
JP (1) JP4799666B2 (enExample)
KR (1) KR101130146B1 (enExample)
CN (1) CN101573114A (enExample)
AR (1) AR064545A1 (enExample)
AU (1) AU2007341356B2 (enExample)
BR (1) BRPI0720829B8 (enExample)
CA (1) CA2673667A1 (enExample)
CL (1) CL2007003830A1 (enExample)
CO (1) CO6190613A2 (enExample)
CR (1) CR10846A (enExample)
CY (1) CY1116350T1 (enExample)
DK (1) DK2114405T3 (enExample)
EC (1) ECSP099471A (enExample)
ES (1) ES2535040T3 (enExample)
HR (1) HRP20150573T1 (enExample)
HU (1) HUE025032T2 (enExample)
MA (1) MA31029B1 (enExample)
MX (1) MX2009006859A (enExample)
MY (1) MY188367A (enExample)
NO (1) NO342150B1 (enExample)
NZ (1) NZ577502A (enExample)
PE (1) PE20081556A1 (enExample)
PL (1) PL2114405T3 (enExample)
PT (1) PT2114405E (enExample)
RS (1) RS53910B1 (enExample)
RU (1) RU2463295C2 (enExample)
SI (1) SI2114405T1 (enExample)
TW (1) TWI388552B (enExample)
UA (1) UA100232C2 (enExample)
WO (1) WO2008080821A1 (enExample)
ZA (1) ZA200904423B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0720829B8 (pt) 2006-12-28 2021-05-25 Hoffmann La Roche formas cristalinas de glyt1, seu método de preparação, seu uso e composição farmacêutica que as compreende
WO2010099323A1 (en) 2009-02-26 2010-09-02 Thar Pharmaceuticals, Inc. Crystalization of pharmaceutical compounds
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
US9328101B2 (en) * 2012-05-25 2016-05-03 Basf Se Crystalline form B of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2H-benzo[B][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione
US8927412B1 (en) * 2013-08-01 2015-01-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-chip package and method of formation
MX354615B (es) * 2013-10-02 2018-03-08 Centro De Investig Y De Estudios Avanzados Del I P N Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus.
KR20220125326A (ko) 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법
WO2022014395A1 (ja) * 2020-07-13 2022-01-20 日本碍子株式会社 精製方法
CN117979967A (zh) * 2021-05-14 2024-05-03 迪斯克医药公司 用甘氨酸转运蛋白抑制剂治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法
EP4347023A4 (en) * 2021-05-27 2025-04-16 Disc Medicine, Inc. Method for treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154370A0 (en) 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
NZ544820A (en) * 2003-08-11 2009-02-28 Hoffmann La Roche Piperazine with or-substituted phenyl group and their use as GlyT1 inhibitors
BRPI0720829B8 (pt) 2006-12-28 2021-05-25 Hoffmann La Roche formas cristalinas de glyt1, seu método de preparação, seu uso e composição farmacêutica que as compreende

Also Published As

Publication number Publication date
BRPI0720829B1 (pt) 2020-04-07
EP2114405B1 (en) 2015-03-11
AR064545A1 (es) 2009-04-08
RS53910B1 (sr) 2015-08-31
ZA200904423B (en) 2010-05-26
JP2010514725A (ja) 2010-05-06
NO20092358L (no) 2009-06-22
NZ577502A (en) 2012-02-24
MY188367A (en) 2021-12-06
CN101573114A (zh) 2009-11-04
US20130197225A1 (en) 2013-08-01
ES2535040T3 (es) 2015-05-04
MX2009006859A (es) 2009-07-03
NO342150B1 (no) 2018-04-03
US8039473B2 (en) 2011-10-18
KR101130146B1 (ko) 2012-03-28
JP4799666B2 (ja) 2011-10-26
UA100232C2 (uk) 2012-12-10
US20080214561A1 (en) 2008-09-04
CY1116350T1 (el) 2017-03-15
PL2114405T3 (pl) 2015-08-31
BRPI0720829B8 (pt) 2021-05-25
RU2009124113A (ru) 2011-02-10
PT2114405E (pt) 2015-06-02
PE20081556A1 (es) 2008-11-28
MA31029B1 (fr) 2009-12-01
ECSP099471A (es) 2009-07-31
RU2463295C2 (ru) 2012-10-10
AU2007341356B2 (en) 2013-08-29
EP2114405A1 (en) 2009-11-11
TWI388552B (zh) 2013-03-11
US20110295007A1 (en) 2011-12-01
WO2008080821A1 (en) 2008-07-10
DK2114405T3 (en) 2015-04-07
CR10846A (es) 2009-08-12
KR20090094166A (ko) 2009-09-03
US20120309969A1 (en) 2012-12-06
HRP20150573T1 (xx) 2015-07-03
US20100311971A1 (en) 2010-12-09
BRPI0720829A2 (pt) 2014-02-25
TW200833677A (en) 2008-08-16
CL2007003830A1 (es) 2008-07-11
HUE025032T2 (en) 2016-02-29
CO6190613A2 (es) 2010-08-19
SI2114405T1 (sl) 2015-06-30
AU2007341356A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
US8039473B2 (en) Solid forms of [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone
CA2673444C (en) Polymorphs of a mglur5 receptor antagonist
CA3073936A1 (en) Ribociclib salts and solid state forms thereof
HK1136207A (en) Crystalline forms glyt1
WO2025106462A1 (en) 2-(4-(2-(7, 8-dimethyl-[1,2,4]triazolo[1,5-a] pyridin-6-yl)-3-isopropyl-1h-indol-5-yl)piperidin-1-yl)acetamide salt and crystalline forms thereof
BRPI0720954B1 (pt) Forma cristalina do sal de monossulfato de um antagonista de receptor mglur5, seu uso, processo de preparação do mesmo e composição farmacêutica que o compreende

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20170918